Yusuke Oji, Naoki Kagawa, Hideyuki Arita, Norifumi Naka, Ken-Ichiro Hamada, Hidetatsu Outani, Yasushi Shintani, Yoshito Takeda, Eiichi Morii, Kenzo Shimazu, Motoyuki Suzuki, Sumiyuki Nishida, Jun Nakata, Akihiro Tsuboi, Miki Iwai, Sae Hayashi, Rin Imanishi, Sayaka Ikejima, Mizuki Kanegae, Masahiro Iwamoto, Mayu Ikeda, Kento Yagi, Haruka Shimokado, Hiroko Nakajima, Kana Hasegawa, Soyoko Morimoto, Fumihiro Fujiki, Akira Nagahara, Atsushi Tanemura, Yutaka Ueda, Tsunekazu Mizushima, Masato Ohmi, Takayuki Ishida, Manabu Fujimoto, Norio Nonomura, Tadashi Kimura, Hidenori Inohara, Seiji Okada, Haruhiko Kishima, Naoki Hosen, Atsushi Kumanogoh, Yoshihiro Oka, Haruo Sugiyama
No standard treatment has been established for most rare cancers. Here, we report a clinical trial of a biweekly WT1 tri-peptide-based vaccine for recurrent or advanced rare cancers. Due to the insufficient number of patients available for a traditional clinical trial, the trial was designed for rare cancers expressing shared target molecule WT1. The recruitment criteria included WT1-expressing tumors as well as HLA-A*24:02 or 02:01. The primary endpoints were immunoglobulin G (IgG) antibody (Ab) production against the WT1-235 cytotoxic T lymphocyte (CTL) epitope and delayed-type hypersensitivity (DTH) skin reactions to targeted WT1 CTL epitopes...
January 6, 2023: Cancers